Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Accord Medicines's quarterly Other Current Payables
declined
from Dec. 2025 (HK$1,650 Mil) to Mar. 2026 (HK$1,587 Mil) but then
increased
from Mar. 2026 (HK$1,587 Mil) to Jun. 2026 (HK$1,708 Mil).
China National Accord Medicines's annual Other Current Payables
increased
from Dec. 2023 (HK$2,035 Mil) to Dec. 2024 (HK$2,159 Mil) but then
declined
from Dec. 2024 (HK$2,159 Mil) to Dec. 2025 (HK$1,650 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines Other Current Payables Chart
China National Accord Medicines Other Current Payables Calculation
Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.
What does a Other Current Payables of HK$1,708 Mil mean?
China National Accord Medicines (SZSE:200028) has a Other Current Payables of HK$1,708 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on China National Accord Medicines and its competitors.
Is China National Accord Medicines' Other Current Payables too high?
China National Accord Medicines' current Other Current Payables is HK$1,708 Mil. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Other Current Payables compare to MCK and COR?
China National Accord Medicines' Other Current Payables of HK$1,708 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Distribution company?
A good Other Current Payables depends on the Medical Distribution industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on China National Accord Medicines and its competitors. China National Accord Medicines's current Other Current Payables is HK$1,708 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.64, compared to a current price of HK$12.07 — trading 11.5% below its estimated fair value. The current Other Current Payables is HK$1,708 Mil. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current Other Current Payables is HK$1,708 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.07 is trading 11.5% below its estimated GF Value™ of HK$13.64.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
Other Current Payables: HK$1,708 Mil
GF Value™: HK$13.64 vs. price of HK$12.07 (11.5% below fair value)
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
